Alison Conlin
Overview
Explore the profile of Alison Conlin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
601
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Michel A, Yi H, Amenta J, Collins N, Vaynrub A, Umakanth S, et al.
BMC Med Inform Decis Mak
. 2024 Sep;
24(1):272.
PMID: 39334347
Background: Women with high-risk breast lesions, such as atypical hyperplasia (AH) or lobular carcinoma in situ (LCIS), have a 4- to tenfold increased risk of breast cancer compared to women...
2.
Kyi K, Consagra W, Culakova E, Berkhof L, Janelsins M, Conlin A, et al.
J Geriatr Oncol
. 2024 Apr;
15(5):101764.
PMID: 38616158
No abstract available.
3.
Calfa C, Rothe M, Mangat P, Garrett-Mayer E, Ahn E, Burness M, et al.
JCO Precis Oncol
. 2024 Feb;
8:e2300513.
PMID: 38354330
Purpose: The Targeted Agent and Profiling Utilization Registry Study is a phase II basket trial evaluating the antitumor activity of commercially available targeted agents in patients with advanced cancer and...
4.
Page D, Pucilowska J, Chun B, Kim I, Sanchez K, Moxon N, et al.
NPJ Breast Cancer
. 2023 Jun;
9(1):53.
PMID: 37344474
Chemoimmunotherapy with anti-programmed cell death 1/ligand 1 and cytotoxic chemotherapy is a promising therapeutic modality for women with triple-negative breast cancer, but questions remain regarding optimal chemotherapy backbone and biomarkers...
5.
Tolaney S, Beeram M, Beck J, Conlin A, Dees E, Puhalla S, et al.
Front Oncol
. 2022 Feb;
11:810023.
PMID: 35223458
Background: Cyclin-dependent kinases (CDK) 4 and 6 regulate G1 to S cell cycle progression and are often altered in cancers. Abemaciclib is a selective inhibitor of CDK4 and CDK6 approved...
6.
Salerno E, Culakova E, Kleckner A, Heckler C, Lin P, Matthews C, et al.
J Clin Oncol
. 2021 Aug;
39(29):3283-3292.
PMID: 34406822
Purpose: Physical activity (PA) is a promising intervention for cancer-related cognitive decline, yet research assessing its use during chemotherapy is limited. This study evaluated patterns of PA before, during, and...
7.
Gilmore N, Mohile S, Lei L, Culakova E, Mohamed M, Magnuson A, et al.
Breast Cancer Res
. 2021 Feb;
23(1):19.
PMID: 33546731
Background: Frailty is associated with an increased risk of chemotherapy toxicity. Cellular markers of inflammation can help identify patients with frailty characteristics. However, the role of cellular markers of inflammation...
8.
Loh K, Mohamed M, Kadambi S, Culakova E, Xu H, Magnuson A, et al.
Oncologist
. 2021 Feb;
26(4):310-317.
PMID: 33523583
Background: Caregivers of adults with cancer often report a different understanding of the patient's prognosis than the oncologist. We examine the associations of caregiver-oncologist prognostic concordance with caregiver depressive symptoms,...
9.
Verduzco-Aguirre H, Babu D, Mohile S, Bautista J, Xu H, Culakova E, et al.
J Pain Symptom Manage
. 2020 Aug;
61(2):369-376.e1.
PMID: 32822750
Context: Older adults with advanced cancer face uncertainty related to their disease and treatment. Objectives: To evaluate the associations of uncertainty with psychological health and quality of life (QoL) in...
10.
Lin N, Borges V, Anders C, Murthy R, Paplomata E, Hamilton E, et al.
J Clin Oncol
. 2020 May;
38(23):2610-2619.
PMID: 32468955
Purpose: In the HER2CLIMB study, patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer with brain metastases (BMs) showed statistically significant improvement in progression-free survival (PFS) with tucatinib....